Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/28/2025 | $9.00 | Buy | Ascendiant Capital Markets |
10-Q - Allarity Therapeutics, Inc. (0001860657) (Filer)
NT 10-Q - Allarity Therapeutics, Inc. (0001860657) (Filer)
8-K - Allarity Therapeutics, Inc. (0001860657) (Filer)
- Successfully initiated enrollment in advanced Phase 2 ovarian cancer trial - Expanded global IP protection by securing Australian patent acceptance for the stenoparib DRP® companion diagnostic- Secured new service contract with EU biotech for Allarity Medical Laboratory TARPON SPRINGS, Fla., August 15, 2025 -- Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway inhibitor—today reported financial results and provided an update on operational highlights for the second quarter ended June 30, 2025. "The second quarter of 2025 marked a period
TARPON SPRINGS, Fla., July 15, 2025 -- Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway inhibitor, today announced the signing of a new commercial agreement with a non-disclosed EU-based biotechnology company. The agreement provides the partner with a non-exclusive global license to a range of selected proprietary Allarity DRP® algorithms in breast cancer, alongside laboratory services from Allarity's Medical Laboratory in Denmark. Under the agreement, Allarity will supply advanced transcriptome analysis services to support the part
TARPON SPRINGS, Fla., July 7, 2025 -- Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway inhibitor—as a personalized cancer treatment using its proprietary, drug-specific Drug Response Predictor (DRP®) patient selection technology, today announced the appointment of Jeff Ervin as the Company's new Chief Financial Officer (CFO). He succeeds Alexander Epshinsky, who will remain engaged with the Company during a transition period. Mr. Ervin brings nearly two decades of executive leadership experience across the healthcare, biotech, and other
Ascendiant Capital Markets initiated coverage of Allarity Therapeutics with a rating of Buy and set a new price target of $9.00
3 - Allarity Therapeutics, Inc. (0001860657) (Issuer)
4/A - Allarity Therapeutics, Inc. (0001860657) (Issuer)
4/A - Allarity Therapeutics, Inc. (0001860657) (Issuer)
TARPON SPRINGS, Fla., July 7, 2025 -- Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway inhibitor—as a personalized cancer treatment using its proprietary, drug-specific Drug Response Predictor (DRP®) patient selection technology, today announced the appointment of Jeff Ervin as the Company's new Chief Financial Officer (CFO). He succeeds Alexander Epshinsky, who will remain engaged with the Company during a transition period. Mr. Ervin brings nearly two decades of executive leadership experience across the healthcare, biotech, and other
TARPON SPRINGS, Fla., June 11, 2025 -- Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway inhibitor—as a personalized cancer treatment using its proprietary, drug-specific Drug Response Predictor (DRP®) patient selection technology—today announced that Jesper Høiland has been appointed to join the Company's Board of Directors. He will be replacing Joseph Vazzano, who will resign from the Board effective on June 30, 2025, following his valuable contributions to Allarity's development over the past two years. Mr. Høiland is already well-acqua
Cash balance at $18.5 millionStrengthened leadership team with new members driving stenoparib developmentNASDAQ compliance regained Boston (November 14, 2024)—Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments using its proprietary, drug-specific patient selection technology, today reported financial results for the third quarter ended September 30, 2024, and provided an update on recent operational highlights. "This quarter's progress marks a steady period of advancement for Allarity as we have maintained a strong cash position, achieved record patient duratio
- Successfully initiated enrollment in advanced Phase 2 ovarian cancer trial - Expanded global IP protection by securing Australian patent acceptance for the stenoparib DRP® companion diagnostic- Secured new service contract with EU biotech for Allarity Medical Laboratory TARPON SPRINGS, Fla., August 15, 2025 -- Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway inhibitor—today reported financial results and provided an update on operational highlights for the second quarter ended June 30, 2025. "The second quarter of 2025 marked a period
- Phase 2 Trial of Stenoparib Concluded Early due to Clear Clinical Benefits Achieved - On Track to Regain Compliance with All Nasdaq Listing Requirements - No Variable Priced Securities are Outstanding - Warrant Overhang Near Elimination - Allarity Withdraws its Form S-1 - Establishes Equity of $15 Million - Cash Balance of $14 Million Boston (May 14, 2024)—Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today reported financial results and provided an update on recent operational highlights for the first quarter that ended March 31, 2024. "The s
Press release Cambridge, MA U.S.A. (November 15, 2022) — Allarity Therapeutics, Inc. ("Allarity" or the "Company"), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP® companion diagnostics for personalized cancer care today reported financial results for the third quarter ended September 30, 2022. Balance Sheet: As of September 30, 2022, Allarity's cash was $3.9 million, as compared to $19.6 million as of December 31, 2021. R&D Expenses: Research and Development (R&D) expenses were $3.0 million for the three months ended September 30, 2022, as compared to $1.4 million for the three months ended September 30, 2021. G&A Expenses:
SC 13G/A - Allarity Therapeutics, Inc. (0001860657) (Subject)
SC 13G - Allarity Therapeutics, Inc. (0001860657) (Subject)
SC 13G/A - Allarity Therapeutics, Inc. (0001860657) (Subject)